Fig 1: Expression pattern of RPS11 in tumor and normal tissues of TCGA database. Distributions of RPS11 expression levels among diverse tumor and normal tissues were displayed in the form of box plots (red: tumor tissue; blue: normal tissue). The color of column would turn to gray when the data of normal tissues was available. Box plot was comprised of median, upper and lower quartiles, and 1.5× interquartile range. The expression level of RPS11 in each sample was plotted as a point. *, P<0.05; **, P<0.01; ***, P<0.001. TCGA, The Cancer Genome Atlas; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical and endocervical cancer; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell cancer; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SRAC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
Fig 2: Expression level and prognostic value of RPS11 in HCC. (A) Representative immunohistochemistry (IHC) pictures of strong, moderate, weak and negative RPS11 staining in HCC tissues. Scale bars: 500 µm (upper lane) and 50 µm (lower lane). (B,C) Kaplan-Meier survival curves for overall survival (OS) and recurrence-free survival (RFS) in high and low RPS11 expression cohort (n=182). Log-rank test was performed to compare the survival difference between groups. (D) Western blot analysis of RPS11 protein level in seven HCC cell lines and one normal liver cell line (L02). Tubulin served as an internal control. (E) qRT-PCR analysis of RPS11 mRNA level in seven HCC cell lines and a normal liver cell line (L02). Actin served as an internal control. *, P<0.05; **, P<0.01; ***, P<0.001. ns, no significance; HCC, hepatocellular carcinoma.
Fig 3: Enriched pathway profiles of RPS11 based on TCGA liver cancer database. Single-sample gene-set enrichment analysis (ssGSEA) was performed to identify the most significantly differentially expressed gene sets between RPS11 high and low expression group. Rows and columns represent pathways and patients, respectively. The color of each grid represents corresponding ssGSEA score of pathway activity. The upper horizontal bar indicates groups (blue: RPS11-low group; red: RPS11-high group). TCGA, The Cancer Genome Atlas.
Fig 4: Correlation between RPS11 expression and gene expression levels of molecules involved in significant pathways in TCGA HCC database: MYC (A), KRT19 (B), EPCAM (C), MET (D). TCGA, The Cancer Genome Atlas; HCC, hepatocellular carcinoma.
Fig 5: Prognostic nomograms and calibration curves of HCC. (A) The nomogram predicted overall survival (OS) for HCC patients. The value of each variable (RPS11, AFP, tumor size and TNM stage) could be obtained by drawing a vertical line from corresponding variable axis to the points scale. The sum of these values is then positioned on the total point axis. Finally, the probability of 3- or 5-year OS could be calculated by drawing a vertical line from the total point axis to the probability scale. (B) The nomogram predicted recurrence-free survival (RFS) for HCC patients. (C,D) Calibration curves for 3- and 5-year OS of HCC patients. The actual OS and the nomogram-predicted probability of OS are plotted on the Y axis and X axis, respectively. The dotted line along the 45° represents a perfect consistency between observed and predictive values. (E,F) Calibration curves for 3- and 5-year RFS of HCC patients. HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; TNM, Tumor Node Metastasis staging system of AJCC 7th edition.
Supplier Page from Abcam for Anti-Ribosomal protein S11/RPS11 antibody [EPR11487]